Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.35 |
| ▸ | OXTR | P30559 | 1/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10100561 | 0.94 | ABL1 (0.39) | ALKLRRK2ABL1KITMET | |
| SCHEMBL10100776 | 0.93 | NTRK1 (0.40) | ALKLRRK2KITMETPIK3CA | |
| SCHEMBL10100716 | 0.93 | ABL1 (0.36) | ABL1PIK3CAPIK3R1KDRAXL | |
| SCHEMBL10100751 | 0.92 | POLB (0.40) | ALKLRRK2KITMETPIK3CA | |
| SCHEMBL10100778 | 0.92 | LRRK2 (0.42) | ALKLRRK2KITMETPIK3CA | |
| SCHEMBL10100706 | 0.91 | MET (0.40) | ALKLRRK2KITMETPIK3CA | |
| SCHEMBL10100779 | 0.90 | MET (0.43) | ALKLRRK2KITMETPIK3CA | |
| SCHEMBL10100756 | 0.89 | KDR (0.40) | ALKLRRK2KITMETPIK3CA | |
| SCHEMBL10100747 | 0.89 | ALK (0.45) | ALKLRRK2KITMETKDR | |
| SCHEMBL10100777 | 0.89 | SMN1; SMN2 (0.42) | ALKLRRK2KITMETKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | ALK 107/4885LRRK2 856/4885ABL1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.